Dr. Kevin Kalinsky reviews key breast cancer updates discussed at SABCS 2025, including HER2CLIMB-05 and DESTINY-Breast09 in HER2-positive disease, as well as emerging SERD data such as giredestrant in HR-positive breast cancer, highlighting evolving options beyond traditional endocrine therapy.
